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1.1 Cancer immunotherapy 
1.1.1 Hallmarks of cancer 
Two decades ago, Hanahan and Weinberg eloquently dubbed the rules that govern the 
neoplastic transformation of healthy cells and tissues into malignant cancer as the hallmarks 
of cancer (Hanahan et al. 2000) . They broke these hallmarks down into six acquired 
alterations in cellular physiology: self-sufficiency in growth signals, evasion of apoptosis, 
insensitivity to anti-growth signals, limitless replicative potential, tissue invasion and 
metastasis and sustained angiogenesis. These hallmarks are all underpinned and 
accelerated by genomic instability, creating heterogeneity and inflammation (Hanahan et al. 
2011).  
 
Over the time period it takes for a tissue pathology to develop into a neoplastic lesion, 
intermediate evolutionary pre-malignant steps are passed, as cells begin to circumvent 
natural cell breaks and suppressive mechanisms. An accumulation of multiple driver 
mutations each conferring a type of growth advantage, is a sequential and stochastic 
process that slowly turns healthy cells cancerous (Balmain et al. 1993, Negrini et al. 2010) . 
Underlying factors behind these alterations can be both inherited and acquired. These 
mutations can affect two categories of genes, oncogenes and tumor suppressor genes. 
Oncogenes bestow cancer cells with a dominant gain of function, and often play a role in 
the stimulation of controlled cellular proliferation. Tumor suppressor genes are behind the 
changes that result in a recessive loss of function (Weinberg et al. 1994) . One example is 
p53, a tumor suppressor gene that plays a role in the regulation or progression of a cell 
through the cell cycle, and its arrest in the presence of DNA damage. If mutated, the ability 
of the cell to control its progression through the cell cycle, as part of the DNA damage 
response, becomes dysregulated (Negrini et al. 2010).  
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1.1.2 The role of the immune system in tumor progression 
The idea that the immune system acts as a sentinel, in recognizing and eliminating newly 
transformed cells is the basis for the longstanding theory of immunosurveilance, first 
established by Burnet and Thomas in 1957 (Burnet et al. 1957) . Built upon this is the 
concept of immunoediting, outlining the dual role the immune system plays in protecting the 
host from tumor formation while simultaneously driving tumor cell evolution (Dunn et al. 
2002, Dunn et al. 2004) . The process by which the immune system copes with tumor growth 
is understood across three stages of tumor development: elimination, equilibrium and 
escape. In the elimination phase, transformed cells express differentially expressed antigens 
that make them more easily targetable by immune cells. This process drives the clonal 
evolution of tumor cells, eventually allowing them to enter the equilibrium phase. Despite 
managing to control tumor growth, immune evasion mechanisms prevent complete tumor 
cell eradication. The progressive development of these mechanisms, together with an ability 
to shape their environment and the very immune cells they are evading, inevitably enables 
tumor escape (Schreiber et al. 2011, O’Donnell et al. 2019).  
 
Tumor cells interact with different types of stromal cells (such as mesenchymal stromal 
cells), cancer-associated fibroblasts, and immune cells (such as myeloid-derived suppressor 
cells and T cells), collectively referred to as the tumor microenvironment (TME) (Joyce et al. 
2009, Rabinovich et al. 2007, Sakaguchi et al. 2008)  The TME plays a crucial role in both 
the development and survival of cancer cells. Inter-cellular bi-directional cross-talk between 
stromal and immune cells in the TME, including the release of pro-tumoral cytokines (e.g. 
IL-6, IL-10 and IL-22), growth factors (e.g. TGF-b, VEGF and PDGF) and matrix remodelling 
enzymes (e.g. MMPs) supports and shapes this milieu (Voigt et al. 2017, Nawaz et al. 
2018,Gorelik et al. 2002,Gerlini et al. 2004, Kurte et al. 2004) . These play important roles 
in tumorigenesis, as they shape an environment that is most favourable for tumor growth, 
enabling malignant cells to escape the host’s anti-tumor immune responses (Hanahan et al. 
2011).  
 
1.2 Adoptive T cell therapy 
A disrupted equilibrium within the TME is often a crucial enabling factor for tumor formation. 
Immunotherapy, which is based on the exploitation of the autologous immune response to 
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a neoplastic process, is an effective, and in some cases curative cancer therapy that aims 
to shift the balance back in favour of the anti-tumoral immune response (Mellor et al. 
2003,Schneider et al. 2006,Pardoll et al. 2012) . T cells are plastic immune cells that have 
been implicated to play diverse roles in driving and controlling tumor growth. Nevertheless, 
T cells have repeatedly been shown to be effective and dynamic mediators of anti-tumoral 
immunity, and their therapeutic use is termed adoptive T cell therapy (ACT) (June et al. 
2007, Kalos et al. 2013).  
 
ACT requires the harvest, expansion and re-infusion of Teff cells into a patient (Melief et al. 
1992) . ACT initially depends on the ability to genetically engineer or select for cells with 
targeted antigen specificity. Beyond this, one must be able to induce these cells to 
proliferate, persist and survive, and mediate their anti-tumoral effector functions (Rosenberg 
et al. 2015).  
 
Three independent ACT approaches have stemmed from the idea that tumor-specific T cells 
could eliminate cancer. Tumor infiltrating lymphocyte (TIL) therapy was the first approach to 
be implemented and relied on the harvest of T cells directly from a tumor, before their ex 
vivo expansion, activation and ultimate reinfusion back into the patient. This approach is 
advantageous because it does not harbour the risks associated with genetic engineering.  
However, scarce access to resectable tumors or metastases, labour-intensive T cell 
preparation and limited numbers of tumor-reactive T cell clones have so far hampered this 
strategy’s success (Rosenberg et al. 1988, Wu et al. 2012).  
 
The other two approaches rely on genetic engineering to confer T cells, isolated from 
peripheral blood, with a specificity to recognize tumor antigens via carefully engineered 
constructs. T cell receptor (TCR)-engineered T cells started being generated to confront 
some of the drawbacks of TIL therapy. Using viral transduction, isolated T cells are 
genetically engineered to possess tumor-specificity through recognition of MHC-restricted 
peptides (June et al. 2007) . Binding of these peptides by the TCR activates T cells and 
induces a cytotoxic response. TCR-mediated specificity is restricted as a result of a reliance 
on the expression of tumor antigens through their MHC complexes (Harris et al. 2016) . The 
final ACT approach, the use of chimeric antigen receptor (CAR)-modified T cells, will be 
discussed in greater detail in the next section. 
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1.3 Synthetic receptors in T cell therapy 
CAR T cell therapy is a leading adoptive T cell therapy (ACT) approach. CARs are synthetic 
constructs use a single-chain variable fragment (scFv) to bind surface-bound target 
antigens.  
 
In the initial concept, the target-binding domain was linked to a cytoplasmic signalling 
subunit made up of part of the cluster of differentiation (CD)-3 ζ chain, that would trigger T 
cell activation following antigen binding. More precisely, these two gene segments are linked 
via a transmembrane domain and an extracellular hinge module, coming together to form 
the simplest form of a CAR, known as a first-generation CAR. The TCR CD3ζ chain contains 
three immuno-tyrosine activation motifs (ITAMs) (Wange et al. 1996) . As a result, this 
module alone can propagate a strong signal 1 without needing the rest of the TCR-CD3 
complex (the gamma, delta and epsilon chains) (Geiger et al. 1999, Haynes et al. 2001).  
 
Signalling is started when ITAMs are phosphorylated by lymphocyte-specific protein tyrosine 
kinase (Lck) within the endodomain of CD3. Building on this, strides taken to ameliorate the 
CAR molecule gave rise to second and third generation CAR structures that incorporated 
signalling cytoplasmic domains, such as CD28, 41BB, and ICOS, in efforts to recapitulate 
the added signal that is delivered following TCR recognition by antigen presenting cells 
(APCs) (Porter et al. 2011, Guedan et al. 2014).  
 
This co-stimulatory signal, where in the case of CD28 for example is driven by 
phosphoinositide 3-kinase PI3K (Krogsgaard et al. 2005, Zhang et al. 2017) is needed for 
full T cell activation (Love et al. 2010) . Additional advances into next (fourth or fifth) 
generation CAR T cells incorporated cytoplasmic signalling components from cytokine 
receptors or inflammatory cytokines, such as IL-12 or IL-18, with an inducible expression 
(Kerkar et al. 2010, Chmielewski et al. 2014).  
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1.4 Bispecific antibodies 
Proteins made up of fragments from two different monoclonal antibodies, brought together 
to recognize two different epitopes or antigens are broadly referred to as bispecific 
antibodies (BiAbs). These man-made antibody-based molecules were first described over 
50 years ago by Nisonoff and colleagues (Nisonoff et al. 1960)  who combined two antigen-
binding sites in one molecule. Naturally occurring bivalent antibodies contain identical 
binding sites which are made up of determinants from both the heavy (H) and the light (L) 
chain. An initial challenge for BiAb development was the chain association issue, which 
resulted in the unwanted pairings of heavy and light chains. As a result, obtaining a 
functional BiAb from a mixture of ten potential H2L2 recombinations (through the co-
expression of two H and two different L chains) was tedious to say the least. Over the years, 
numerous strategies emerged with the goal of improving the yield as well as homogeneity 
of the final product (Brinkmann et al. 2017).  
 
The generation of fragment-based formats – an approach that simply combines several 
antibody-binding regions (Ab fragments) – was a simple and effective approach that 
effectively circumvented the chain-association issue (Birch et al. 2006) . The format lacks 
an Fc region, while facile co-expression of the polypeptide chains in lower expression 
systems (eukaryotic or prokaryotic) was cost-effective and reaped higher yields. Fc-deficient 
formats are however susceptible to catabolism by the neonatal Fc receptor and have a 
shorter half-life as a result (Demarest et al. 2008, Lowe et al. 2011).  
 
The development of the ‘knob-into-hole’ (KiH) technology enabled correct heavy chain 
heterodimerization (Ridgway et al. 1996, Merchant et al. 1998) . Importantly, correct light 
chain association in bispecific heterodimeric IgG antibodies was eventually also enabled by 
the development and description of immunoglobulin domain crossover ‘CrossMAb’ 
technology (Schaefer et al. 2011) . The technology relies on antibody domain crossover 
within one Fab-arm of a bispecific IgG antibody in order to allow for correct chain association, 
whereas correct heavy chain association can be ensured by, amongst other approaches, 
KiH and electrostatic steering (Ridgway et al. 1996, Gunasekaran et al. 2010) . Using 
domain crossover, any antibody pair can be used to derive many of the formats that have 
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been described since, including bivalent 1+1, trivalent 2+1 and tetravalent 2+2 (Labrijn et al. 
2019).  
 
Figure 1: A selection of BiAb formats. Various antibody formats with multiple valencies, binding arms, half-
lives and functions. Left to right. Tandem scFvs with two monovalent binding arms and no Fc-region. 1+1 
asymmetric with two monovalent binding arms and an Fc region. 1+2 asymmetric with bivalent for one antigen 
1 and monovalent for antigen 2, also has an Fc region. 2+2 symmetric bivalent for both antigens and contains 
an Fc region. BiAbs that are Fc-deficient have a relatively short half-life due to a lack of protection from the 
neonatal Fc receptor, FcRn. The P329G LALA mutation abolishes FcyR binding, silencing the Fc region. 
 
1.5. The synergy of BiAbs with ACT 
Earlier work from our group could demonstrate how BiAbs can be synergised with ACT for 
improved anti-tumoral immunity. Initial work could show that BiAbs specific for both T cell 
and tumor cell could bridge T cells with tumor cells and improve the killing efficiency of tumor 
specific T cells (Kobold et al. 2014) . More recently, the group began to develop the approach 
in efforts to create an MHC-unrestricted platform that could mediate specific and conditional 
T cell activation and tumor cell lysis. To achieve this, specially designed fusion receptors 
named synthetic agonistic receptors (SARs) were developed. SARs are constituted of an 
extracellular domain – itself inert and not present on any naturally occurring T cell – fused 
to intracellular T cell activating domains.  
 
The unique expression of the SAR ectodomain means an exogenous, controllable, modular 
and specific molecule is required for its triggering. Bispecific antibodies (BiAbs) perfectly fit 
that bill, and the importance of BiAb design in the context of SAR activation is described 
below. The combination of SAR-transduced T cells with BiAbs was initially tested in the 
murine setting, where SAR-transduced T cells were shown to be functional and specific. 
Important work that was crucial for this initial characterization was carried out by the former 
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doctoral students Matthias Kurzay, Moritz Luigi Schmidbauer and Clara Karches 
(Schmidbauer, 2018, Karches et al. 2019).  
 
In the context of the work described herein, the SAR construct is made up of an EGFRvIII 
extracellular domain, linked to a CD28 transmembrane domain. Intracellularly, signalling is 
propagated by the intracellular CD28 domain and CD3ζ. EGFRvIII was chosen as the 
extracellular domain, an antigen not present on normal cells and restricted to particular 
tumor entities such as glioblastoma. The rationale in choosing the intracellular domains drew 
from the CAR T cell experience, where several second-generation CARs, including the FDA 
approved Yescarta successfully employ CD3ζ to initiate signal 1 and CD28 for the 
costimulatory signal necessary for full blown T cell activation (Boyiadzis et al. 2018).  
 
Our collaborators at Roche developed a trivalent and bispecific (two specificities for MSLN 
and a single specificity for EGFRvIII) CrossMab. This design was developed with knowledge 
from preliminary studies that demonstrated that a single specificity for EGFRvIII is necessary 
to avoid unwanted and off-tumor cross-linking of the SAR receptor, and the subsequent T 
cell activation that would result. The design included two binding arms (Fab) against MSLN 
to maximize tumor cell binding (Schmidbauer et al. 2018, Karches et al. 2019).  
 
Following some promising results with the SAR-BiAb platform in preliminary murine studies, 
the purpose of this work was to determine the validity and efficacy of this approach in the 
human system. Through the generation of several human pancreatic cancer models, and 
extensive in vitro and in vivo testing, we aimed to characterize this platform. Specific T cell 
activation and target cell lysis, and as well as a demonstration of safety and controllability 
were critical aims in this regard. Through this characterization, we wanted to determine the 
translational relevance and significance of the approach as a stand-alone, next-generation 
adoptive T cell therapy with the potential to plug some pitfalls of current ACT approaches.  
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Figure 2: SAR and CAR T cell constructs. Divergence in design lies in the extracellular domain, where the 
CAR is composed of a scFv, while the SAR has an inert receptor. Additionally, the constructs are made up of 
several components, each of which leading towards the activation, functionality and persistence of the 
transduced T cells. Adapted from (Benmebarek et al. 2019) . 
 
1.6 Characterizing the SAR-BiAb approach in the pancreatic cancer 
setting 
Over recent years, our understanding of T cell biology, heterogeneity and the functional 
divergence that arises from their exposure to different stimuli in various environments has 
drastically improved. T cell stability and plasticity have been shown to be regulated by 
several components; conditions (costimulation and cytokines), clonality and chromatin 
(Murphy et al. 2010) . Cytokines and costimulation are the prime factors affecting T cell 
differentiation and stability (Murphy et al. 2000) . Circuitry is defined as the network of 
interactions between transcription factors, and has also been implicated in stability, 
differentiation, as well as plasticity (Hwang et al. 2005, Zheng et al. 2010, Nurieva et al. 
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2007) . The effect of chromatin modifications on active or repressed genes can be impactful 
on the maintenance of T cell phenotype and plasticity (Zhou et al. 2009, Wilson et al. 2009).  
 
Within the TME, most T cells have been shown to be driven towards a hyporesponsive state 
of exhaustion, characteristically associated with an upregulation in inhibitory receptors, a 
decrease in effector cytokines and impaired cytotoxicity (Jiang et al. 2015,Wherry et al. 
2015). In choosing to characterize the approach in human pancreatic tumor models, we 
sought to learn if SAR T cells can migrate to, infiltrate, and mediate anti-tumoral functions 
against a dense and immunosuppressive microenvironment. The impact of this milieu on 
SAR T cell phenotype and function was also of interest, the understanding of which having 














Figure 3: The SAR-BiAb concept illustrated. Specific and conditional SAR T cell activation can only be 









Based on previous findings, this thesis aims to demonstrate the following: 
1. To characterize the SAR-BiAb platform in the human system specifically looking at 
the requirements for T cell activation and target cell lysis. As such, conditional 
specificity will be evaluated in the presence or absence of the target antigen, as well 
as determining the range and dose-dependent activity of the BiAb. 
2. To visualise the immune synapse at the SAR T cell-target cell interface. Specifically 
evaluating the function as well as characteristics of the synapse in comparison to 
those observed at the CAR or TCR-target cell interfaces. 
3. To demonstrate the inherent safety, modularity and controllability facets of the 
platform in vivo and in vitro 
4. To characterize the in vivo functionality if the platform in solid tumor xenograft models 
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2 Material and Methods 
 
2.1 Machines and reagents 
 
Table 1 Machines and devices 
Machine Manufacturer Origin 
Analytical balance Satorius Laboratory Göttingen, Germany 
Cell culture flow HeraSAFE KS Heraeus, 
ThermoFischerScientific 
Massachusetts, USA 
Centrifuge Rotina 420R Hettich GmbH Tuttlingen, Germany 
ChemiDoc BioRad California, USA 
CO2 – Incubator (BD6220) Heraeus, 
ThermoFischerScientific 
Massachusetts, USA 
FACS Canto II BD Biosciences New Jersey, USA 
FACS Fortessa BD Biosciences New Jersey, USA 
iCELLigence ACEA Biosciences Inc California, USA 
Innova44 Thermoshaker New Brunswick Scientific, 
Eppendorf 
Hamburg, Germany 
Leica TCS SP5 confocal system Leica Microsystems Wetzlar, Germany 
Light microscope Axiovert 40C Zeiss New York, USA 
LightCycler480 System Roche Mannheim, Deutschland 
Multilabel Plate Reader Mithras LB 940 Berthold Bad Wildbad, DE 
Nanodrop 2000c ThermoFischerScientific Massachusetts, USA 
pH 720 WTW inoLab GmbH Weilheim, DE 
PowerPac™ Universal Power 
Supply 
Bio-Rad Laboratories Munich, Germany 
T3 Thermocycler Biometra Göttingen, Germany 
xCELLigence ACEA Biosciences Inc. California, USA 
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Table 2 Reagents   
Reagent Manufacturer Origin 
Albumin fraction V (BSA) Sigma-Aldrich Steinheim, Germany 
Annexin A5 Thermofisher Massachusetts, USA 
Batimstat Sigma-Aldrich Steinheim, Germany 
Calcium chloride Sigma-Aldrich Steinheim, Germany 
CD178 (Fas Ligand) Monoclonal 
Antibody (NOK-1), functional 
grade  
ThermoFischerScientific Massachusetts, USA 
CD178 (Fas Ligand) Monoclonal 
Antibody TNFSF6 
RnD systems Minneapolis, USA 
Cetuximab Apotheke Innenstadt LMU Munich, Germany 
Colagenase D Sigma-Aldrich Steinheim, Germany 
Count Bright, counting beads LifeTechnologies California, USA 
Dimethylsulfoxid (DMSO) Sigma-Aldrich Steinheim, Germany 
DNase I Roche Mannheim, Germany 
Dithiothreitol Sigma-Aldrich Steinheim, Germany 
Dulbecco’s modified Eagles 
medium DMEM 
PAA Pasching, Austria 
Dulbecco’s Phosphate Buffered 
Saline (PBS) 
PAA Pasching, Austria 





EcoRI NEB Massachusetts, USA 
EcoRV NEB Massachusetts, USA 
Egtazic acid (EGTA) Sigma-Aldrich Steinheim, Germany 
Ethanol 100 % Carl Roth GmbH Karlsruhe, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich Steinheim, Germany 
FACSFlow, FACSSafe BD Biosciences New Jersey USA 
GeneJet plasmid mini prep kit ThermoFischerScientific Massachusetts, USA 
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Heparin-sodium 2.500 IE / 5 ml Braun AG Melsungen, Germany 
HEPES-buffer 1 M Sigma-Aldrich Steinheim, Germany 
Human Granzyme B ELISA kit RnD Systems Minneapolis, USA 
Human Interferon gamma ELISA 
kit 
BD Biosciences New Jersey USA 
Human IL-2 ELISA Kit BD Biosciences New Jersey USA 
Human serum Sigma-Aldrich Steinheim, Germany 
Isofluoran CP PHARMA Burgdorf, Germany 
KasI NEB Massachusetts, USA 
LB agar Carl Roth GmbH Karlsruhe, Germany 
LB medium Carl Roth GmbH Karlsruhe, Germany 
LE agarose Biozym Hessisch Oldendorf, Germany 
L-glutamin 200 mM PAA Pasching, Austria 
MEM non-essential amino acids 
(NEAA, 100x) 
Gibco Products New York, USA 
N-Octyl-Beta-Glycopyranoside Sigma-Aldrich Steinheim, Germany 
NotI NEB Massachusetts, USA 
OneComp Beads ThermoFischerScientific Massachusetts, USA 
peqGOLD TriFast PEQ LABS Erlangen, Germany 
Penicillin/ Streptomycin (100x) PAA Pasching, Austria 
Puromycin InvivoGen California, USA 
Propidium Iodide Thermofisher Massachusetts, USA 
Protease Inhibitor Sigma-Aldrich Steinheim, Germany 
Q5 enzyme NEB Massachusetts, USA 
RetroNectin TaKaRa Kyoto, Japan 
RevertAid first strand cDNA 
synthesis kit 
ThermoFischerScientific Massachusetts, USA 
Recombinant human etc. 
Amphiregulin 




SinoBiological Beijing, China 
Recombinant Human 
Betacellulin (Fc Tagged) 
SinoBiological Beijing, China 
Recombinant Human EGF SinoBiological Beijing, China 
Recombinant Human EGF (Fc 
Tagged) 
SinoBiological Beijing, China 
Recombinant human EGFR SinoBiological Beijing, China 
Recombinant Human Epigen PeproTech New Jersey USA 
Recombinant Human Epiregulin PeproTech New Jersey USA 
Recombinant Human Epiregulin 
(Fc Tagged) 
SinoBiological Beijing, China 
Recombinant Human HB-EGF SinoBiological Beijing, China 
Recombinant Human Mesothelin 
(Fc tagged) 
SinoBiological Beijing, China 
Recombinant Human TGF alpha SinoBiological Beijing, China 
Rituximab Apotheke Innenstadt LMU Munich, Germany 
Roswell Park Memorial Institute 
(RPMI) 
PAA Pasching, Austria 
SERVA DNA Stain Clear G SERVA Heidlberg, Germany 
Sodium chloride Sigma-Aldrich Steinheim, Germany 
Sodium pyruvate Gibco Products Pasching, Austria 
Sulphuric acid Apotheke Innenstadt LMU Munich, Germany 
Tissue freezing medium Leica biosystems Nussloch, Germany 
TNF alpha monoclonal antibody 
MP6-XT22 
ThermoFischerScientific Massachusetts, USA 
Trypan blue Sigma-Aldrich Steinheim, Germany 
Trypsin (10x) PAA Pasching, Austria 
Tween 20 Carl Roth GmbH Karlsruhe, Germany 
Urea Sigma-Aldrich Steinheim, Germany 
 15 
 
Table 3 Cell culture media   
Medium Composition Medium Composition 
Human  
T cell 
VLE RPMI  
2 % Human Serum 
2 mM L-Glutamin 
100 IU/ml Penicillin 
100 μg/ml Streptomycin 
1 mM Natrium-Pyruvat 
1 % MEM-NEAA 
50 μM β-Mercaptoethanol 
RD clone medium DMEM 
10 % FBS 
4 mM L-Glutamin 
100 IU/ml Penicillin 
100 μg/ml Streptomycin 
Tumor DMEM 
10 % FBS 
2 mM L-Glutamin 
100 IU/ml Penicillin 
100 μg/ml Streptomycin 
Freezing 90 % FBS 
10 % DMSO 
 
2.2 Molecular biology methods 
2.2.1 Synthetic agonistic receptor cloning via overlap-extension polymerase chain 
reaction 
The fusion of gene segments by overlap-extension PCR is a fast and effective way to create 
chimeric genes encoding novel proteins (Heckman et al. 2007). The human EGFRvIII-CD28-
CD3ζ chimeric receptor construct (E3) is made up of human EGFRvIII (Uniprot Entry P00533 
AA 1-29, 298-646), human CD28 (Uniprot Entry P10747 AA 153-220) and human CD3ζ 
(Uniprot Entry P20963 AA 52-164). The control construct E3del is lacking the intracellular 
signalling domains CD28 and CD3ζ. SAR constructs were generated by Mathias Kurzay, a 
UltraComp eBeads ThermoFischerScientific Massachusetts, USA 
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former doctoral student in the laboratory. All SAR constructs were subsequently inserted 
into the retroviral vector pMP71 (Engels et al. 2003).  
 
2.3 Cell lines 
2.3.1 Tumor cell lines 
The human mesothelin over-expressing cell-lines MIA PaCa-MSLN, SUIT-2-MSLN, and Flp-
In-HEK293-MSLN (HEK-MSLN) were generated by transduction with pMXs (Kitamura 2003) 
containing full-length human mesothelin (MSLN, UNIPROT entry Q13421) cDNA. Likewise, 
the human glioblastoma cell line U251-MG was generated to express full-length human 
EGFRvIII (Uniprot Entry P00533 AA 1-29, 298-646). The cell line MSTO-mesothelin-
luciferase (MSTO-MSLN-LUC) was generated by transducing the MSTO-211H cells with 
lentiviruses (VSV-G pseudotyped) encoding full-length human MSLN and full-length firefly 
luciferase (ffLuc), sequentially. The cells were transduced with lentivirus encoding hMSLN. 
The gene encoding full-length human MSLN was cloned into the MCS of the lentiviral vector 
obtained from System Bioscience, pCDH-EF1a-MCS-T2A-Puro cDNA. The cells were then 
selected with puromycin at 5 µg/mL for 2 to 3 days. Surviving cells were stained and 
confirmed with surface expression of hMSLN. The generated MSTO-MSLN cells were then 
transduced with lentivirus encoding ffLuc. The gene encoding full-length ffLuc was cloned 
into the MCS of the lentiviral vector obtained from System Bioscience, pCDH-CMV-MCS-
EF1a-Neo. The cells were then selected with 5 µg/mL of G418 for 2 to 3 days. 
 
2.3.2 Virus production 
For virus production retroviral pMP71 (kindly provided by C. Baum, Hannover) vectors 
carrying the sequence of the relevant receptor were stably expressed in packaging cell lines. 
Single cell clones were generated and screened for receptor expression levels, then 
screened for levels of virus production by determining the transduction efficiency of primary 
T cells. Using this method, we generated the producer cell lines 293Vec-RD114-E3, 
293Vec-RD114-E3del, and 293Vec‑RD114‑CAR‑MSLN. 293Vec-Galv and 293Vec-RD114 
were grown in DMEM with 10 % fetal bovine serum (FBS, Life Technologies, USA), 1 % 





2.3.3 STR profiling 
All human cell lines were short tandem repeat profiled in house to verify their origin. Cells 
were used for a time period no longer than 2 months. 
 
2.4 Cytotoxicity assays 
T cells were coincubated with tumor cells and BiAb at indicated effector to target ratios and 
concentrations. The coculture conditions between transduced T cells and adherent target 
cells were set-up as indicated. For impedance-based real-time killing assays the 
xCELLigence instrument was used. The cell index parameter denoted is a measure of the 
relative change in electrical impedance, to represent cell status (adherence). All described 
calculations are based on the RTCA software version 1. The BioGlo cytotoxicity assay 
(Promega, USA) system was also used where indicated according to the manufacturer’s 
protocol. 
 
Table 5 Cell lines   
HEK-MSLN DMEM3+ 
Human embryonic kidney cells. Made 
from Flp-In 293- Cell line 
 
ThermoFischerScientific 
A375 DMEM3+ Human melanoma cells 
                                    






Human glioblastoma cells  
 
 
Acquired from ATCC 
SUIT-2 
Human pancreatic ductal 
adenocarcinoma cell line derived form 
a liver metastasis. 
MSTO-211H  Biphasic mesothelioma of the lung 
MIA PaCa-2 Pancreas Carcinoma 
293Vec- Galv  
RD clone 
medium 
Amphotropic packaging cell line. 
Prof. Dr. Manuel Caruso 
(Québec, Canada) 293Vec-RD114 Amphotropic packaging cell line. 
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2.5 Cytokine release assays 
Human T cell stimulation assays were set up at indicated concentrations and effector-to-
target ratios. IFN-γ, IL-2 and Granzyme B were quantified by enzyme-linked immunosorbent 
assay (ELISA). 
 
2.6 Bispecific antibody depletion in vitro assay 
T cell and tumor cell coculture was set up at indicated antibody concentrations and effector-
to-target ratios. SAR T cells were cocultured with BiAb before being added to the tumor 
cells. Anti-MSLN CAR T cells were used as a control and cocultured with tumor cells 
following the same procedure (no BiAb was added). After 24 h (time between each 
depletion) supernatants were collected, and T cells transferred onto a new plate with seeded 
tumor cells. T cells were either re-suspended with medium only or redosed with BiAb to 
control for the depletion. Three sequential assay depletions were performed. IFN-γ 
concentration in the supernatants was quantified by ELISA. 
 
2.7 Animal Experimentation  
2.7.1 Xenograft models 
NSG mice (NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ) were purchased from Charles River. Suit-2-
MSLN and MiaPaCa-MSLN xenograft models were established by subcutaneously injecting 
5 x 105 cells into the right flank. MSTO-MSLN-LUC xenograft model was established by 
subcutaneously injecting 106 cells in a 1:1 ratio of PBS and Matrigel (Corning Life Sciences) 
into the right flank. BiAb and 107 T cells were given intravenously as indicated. For the BiAb 
depletion, redosing schedule and antibody dosage were carried out as indicated. A total of 
six BiAb treatments were injected per mouse at 3, 6, 9, 13, 17, and 19 days after tumor 
injection. Mice were bled 6 hours after antibody redosing. All animal experiments were 
approved by the local regulatory agency (Regierung von Oberbayern) and adhered to the 
NIH guide for the care and use of laboratory animals. Endpoints were registered by an 
observer blinded to the treatment groups as previously defined (Karches et al. 2019).  
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2.7.2 In vivo imaging 
For in vivo imaging, mice were injected with 100 µl of luciferin substrate (prepared according 
to the manufacturer’s instructions) 10 minutes prior to imaging (Xenolight D‑Luciferin 
potassium salt, Perkin Elmer, USA). IVIS Lumina X5 (Caliper Life Sciences, Perkin Elmer, 
USA) was used to acquire in vivo images. The Living Image Software 4.7.2 was used for 
analysis (Perkin Elmer, USA). 
 
2.8 Single cell analysis by flow cytometry 
Flow cytometry was carried out according to a previously published protocol (Voigt et al. 
2017) Spleens were passed through 30 µm cell strainers, following an erythrocyte lysis 
protocol. Tumors were digested with 1.5 µg/ml collagenase IV and 50 U/ml DNAse I for 
30 minutes at 37ºC. Analysis was carried out with a BD FACS Canto II and Fortessa (BD 
Bioscience, Germany).  
 
2.8.1 Flow cytometry staining  
Dead cells were stained using the fixable viability violet dye (Biolegend) for 15 minutes at 
RT. This was followed by the blocking of Fc receptors with TruStain fcX (Biolegend) for 20 
minutes at 4ºC. For phenotype analysis surface staining was performed by anti-human 
CD8a (clone HIT8a, Biolegend), anti-human CCR7 (clone G04387, Biolegend), anti-human 
CD45RO (clone UCHL1, Biolegend), anti-human PD1 (clone EH12.2H7, Biolegend), anti-
human EGFR (APC, clone AY13, Biolegend), anti-human CD45 (clone 2D1,  Biolegend), 
anti-human CD3 (clone HIT3a, Biolegend), and anti-human CD4 (clone OKT4, Biolegend). 
Cells were washed and resuspended in PBS. For cell number quantification CountBright® 
absolute counting beads (Life Technologies) were added.  
 
2.9 Confocal microscopy  
Blinded confocal imaging and conjugate quantification were carried out following the 
selection of 10 representative areas of each slide. Cells in or out of conjugate within each 
area were quantified and a ratio thereof subsequently determined. For each conjugate, the 
position of the microtubule organizing center (MTOC) was observed, and its polarization to 
the immune synapse, or lack thereof, was noted. The ratio of polarized to non-polarized 
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MTOCs was used to determine the ratio of functional synapses out of all conjugates formed. 
Image acquisition and staining are outlined in the supplementary methods. 
 
2.9.1 Confocal image acquisition 
Samples for confocal laser scanning microscopy were examined using a Leica TCS SP5 
confocal system (Leica Microsystems, Wetzlar, Germany), with a HCX PL APO CS 63x/1.4 
oil objective. For z-axis image reconstruction (stacking), confocal sections were taken 0.2 
µm apart, assembled using the Leica application suite v2.7.3.9723 (Leica Camera AG) and 
further processed by the open access program FIJI, based on image J (https://fiji.sc). For 
each marker, at least 20 conjugates were recorded by confocal microscopy per condition. 
 
2.9.2 Confocal microscopy staining 
SAR T cells were stained with anti-human Granzyme-B (clone GB11, BD), anti‑human LFA-
1 (clone CB5.4, BioLegend), anti-alpha tubulin, (clone DM1A, Abcam), anti-human Lck (BD 
Biosciences). F-actin was stained using Phalloidin-iFluor reagent (Abcam). Following 
conjugation in a 96-well V-bottom plate, cells were transferred onto a poly-L-lysine-coated 
(1 µg/ml – Sigma, Germany) microscope slide (ThermoFisherScientific), and were allowed 
to adhere for 30 minutes, Then, fixation, permeabilization (BD Cytofix, BD Biosciences) and 
antibody staining were carried out according to the manufacturer’s instructions. 
 
2.10 Statistical Analysis 
Statistical evaluation was performed using GraphPad Prism software V8.3.1 (San Diego, 
CA, USA). Differences between experimental conditions were analysed as described in the 
figures. P values < 0.05 were considered to be significant. Data are shown as mean values 






3.1. SAR expression and BiAb binding 
In efforts to equip T cells with a controllable activating receptor, we generated a SAR construct 
made up of the extracellular domain of human EGFRvIII, linked to the intracellular CD28 and 
CD3ζ domains - E3. Control construct lacking the intracellular costimulatory domains was also 
generated, herein referred to as - E3del (Figure 1A). Constructs could be retrovirally transduced 
into human T cells with high and comparable efficiencies (Figure 1B).  
 
Figure 1: Schematic drawing of constructs and molecule and retroviral transduction of human CD3+ T cells. 
(A) E3 SAR and E3del construct designs as well as schematic depiction of the 2+1 CrossMab. B) Flow cytometry plot 
depicting exemplary shift in SAR expression of transduced cells, with graph depicting range of transduction efficiencies 
from ten representative donors. Figure showing absolute transduction efficiencies from 10 healthy donors. 
 
Using the CrossMab technology (Schaefer et al. 2011)  a trivalent yet bispecific (2+1) antibody 
(BiAb) with a single specificity for the SAR receptor (EGFRvIII) and two specificities against the 
tumor antigen (MSLN) was generated by collaborators at Roche Glycart (Schlieren, Switzerland) 
(Figure 1A). Previous studies (in the murine system) could demonstrate that BiAbs that are 
bivalent for the SAR receptor resulted in unwanted crosslinking of the receptor upon binding. This 
receptor crosslinking was shown to be abolished when a trivalent format monovalent for the fusion 
protein on the T cell was used.  
 
Before BiAb characterization, its binding curve and kinetics were assessed. To establish a binding 
curve, SAR T cells were coincubated with ascending concentrations of the E3-MSLN BiAb, and 
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binding activity was shown to begin at a concentration of 0.01 μg/ml, before SAR T cell saturation 
was reached at 10 μg/ml (Figure 2A). The binding kinetics of the CrossMab to both its targets 
(MSLN and EGFRvIII) were assessed by recording binding over time using flow cytometry. Using 
a saturating BiAb concentration (15 μg/ml) we could show that the binding kinetics were 
comparable for both targets, with E3 T cells used as the EGFRvIII target and Suit-MSLN tumor 
cells used as the MSLN target (Figure 2B). 
 
We initially assessed whether the trivalent BiAb format (monovalent for the fusion receptor) could 
specifically and conditionally activate the receptor in the human system. Binding assays were set-
up, where SAR T cells were cultured with coated BiAb (immobilized) or soluble BiAb (free), with 
the anti-EGFR monoclonal antibody (mAb) cetuximab used as a positive control, and the anti-
CD20 mAb rituximab used as a negative control. Results demonstrated that only the immobilized 
BiAb was able to induce T cell stimulation in E3 T cells, while E3del and UT T cells were not. As 
expected, cetuximab mediated SAR T cell stimulation while rituximab did not. This SAR T cell 
activation was also shown to occur in a dose dependent manner (Figure 2C and D).  
 
 
Figure 2: BiAb binding kinetics and its capacity to mediate SAR T cell activation. (A) E3-MSLN BiAb binding 
curve. 107 T cells were co-incubated for 1 hour with ascending concentrations of E3-MSLN BiAb – (0.005 µg/ml to 15.0 
µg/ml). (B) 2 + 1 BiAb (EGFRv3 x hMSLN) was pre-labeled with R-Phycoerythrin (PE). A mixture of human E3 SAR T 
cells (Left) and MSTO-MSLN tumor cells (Right) were acquired at the flow cytometer for approximately 30 sec. The 
respective 2 + 1 BiAb was added within 5 sec and BiAb binding was recorded for an additional 200-300 sec. BiAb 
binding was immediate and equal for both target and effector cells. (C) In a 96 well plate, BiAb (5 µg/ml) was either 
coated overnight (bound) or added in soluble form (unbound) with E3, E3del or UT T cells. Soluble and bound 
monoclonal antibodies (rituximab – anti-CD20; cetuximab – anti-EGFR) were added as negative and positive controls, 
respectively. (D) In a 96 well plate, BiAb (0.001 µg/ml to 5.0 µg/ml) was coated overnight (bound) before E3, E3del and 
UT T cells were added. (C and D) Readouts were carried out at 48 h. For each readout, supernatants were collected 
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and a hIFN-γ ELISA readout subsequently carried out. For statistical analysis the unpaired two-tailed student’s t test 
was used. Cytokine release experiments show mean values ± SEM and are representative of three independent 
experiments. 
 
3.2 A closer look at SAR activation requirements 
To further analyze the requirements for T cell activation upon SAR T cell engagement, we used 
natural ligands of EGFR. We found that soluble EGFR ligands did not trigger E3 T cell activation 
when used under physiological conditions (Figure 3A and B). Furthermore, following the inhibition 
of EGFR ligand shedding from the tumor cell surface (using the A375 cell line) via the addition of 
the matrix metalloprotease inhibitor batimastat, SAR T cells were not activated by the upregulated 
membrane bound ligands compared to the positive control, though basal activation – lower by 
more than a 100-fold – was observed (Figure 3C). In contrast, Fc-tagged EGF immobilized to the 
well induced similar activation to EGFR-binding antibodies immobilized in the same way. This 





Figure 3: The impact of natural and soluble EGFR ligands on SAR T cell activation. (A) Quantification of T cell 
stimulation as measured by IFN-γ (A) and IL-2 (B), following coculture of E3 T cells with known EGFR ligands in their 
soluble as well as Fc-bound forms. Plate-bound cetuximab (5 μg/ml) was used as a positive control. (C) Quantification 
of T cell stimulation following coculture of E3 T cells with A375 tumor cells (E:T 10:1). The metalloprotease inhibitor 
Batimastat was added (10 uM) to prevent EGFR ligand shedding. Readouts were carried out at 48 h. For statistical 
analysis the unpaired two-tailed student’s t test was used. Experiments show mean values ± SEM and are 
representative of two independent experiments.  
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3.3 BiAb-mediated effects on SAR T cell activation in presence of target cells 
Having shown that BiAb-mediated T cell activation is strictly dependent on the crosslink to the 
target cells, we further assessed this conditional T cell activation. We incubated healthy donor 
SAR-transduced T cells with the 2+1 CrossMab in the absence or presence of MSLN-expressing 
pancreatic and mesothelioma cancer cell-lines MiaPaca-MSLN, Suit-MSLN, and MSTO-MSLN, 
with untransduced and E3del-transduced T cells serving as controls. Importantly, only E3 T cells 
in the presence of the BiAb as well as the target antigen were shown to produce IFN-γ in a dose-
dependent manner, whereas UT and E3del-transduced T cells were not stimulated even in the 
presence of both BiAb and target molecules (Figure 4A, B and C). 
 
Figure 4: Human SAR T cells are specifically stimulated by anti-human mesothelin x anti-EGFRv3 2 + 1 BiAb 
in presence of mesothelin+ target cells in vitro. (A and B) Quantification of E3, E3del or UT T cell activation when 
co-cultured with Suit-2-MSLN (A) or HEK-MSLN (B) cells and 2 + 1 BiAb (5 μg/ml, E:T - 10:1). (C) Quantification of E3, 
E3del or UT T cell activation when co-cultured with MiaPaca-MSLN tumor cell and increasing concentrations of 2 + 1 
BiAb (0.001, 0.005, 0.01, 0.05, 1 or 5 μg/ml, E:T 10:1). For statistical analysis the unpaired two-tailed Student’s t test 





3.4 SAR-transduced T cells form functional immunological synapses, to 
mediate efficient tumor-cell lysis 
MSLN-expressing tumor cells (Suit-02-MSLN and MiaPaca-MSLN) were effectively targeted and 
lysed by E3 T cells together with E3-MSLN BiAb, but not by E3del and UT T cells. By assessing 
killing data in real-time, and by employing various effector to target ratios (10:1, 5:1, 1:1), we were 










Figure 5: Human SAR T cells mediate specific and conditional tumor cell lysis of mesothelin+ target cells. (A 
and B) Real-time quantification of MiaPaca-MSLN (A) or Suit-MSLN (B) tumor cell lysis by E3 or E3del T cells and 2 + 
1 BiAb at either 10:1, 5:1 or 1:1 effector to target ratios.  Experiments shown are representative of 3 independent 
experiments. Impedance-based cytotoxicity assays were performed in duplicates for technical reasons. For statistical 
analysis, the total curve over time was compared. 
 
To further control for the specificity of T cell activation and killing, we coincubated E3 SAR T cells 
with two cell lines, one expressing EGFRvIII (U251) and the other expressing MSLN (MiaPaca-
MSLN). We could show that the EGFRvIII expressing cell line could not induce E3 T cell 
activation, in contrast to the MSLN-expressing one (Figure 6A). This was further supported by 
comparing the two in a real-time killing assay, where we saw no killing of the EGFRvIII-expressing 
cell-line compared to the MSLN expressing one (Figure 6B and C).  
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Figure 6: E3-MSLN BiAb activates and redirects SAR T cells in presence of cells expressing mesothelin but 
not EGFRvIII. (A) Quantification of T cell stimulation as measured by IFN-γ (left) and IL-2 (right), following coculture of 
E3 or UT (WT) T cells with MSLN-expressing MiaPaca-MSLN or EGFRvIII-expressing U251-EGFRvIII and 2 + 1 BiAb 
(5 μg/ml). (B) Real-time quantification of MiaPaca-MSLN (B) or U251-EGFRvIII (C) tumor cell lysis by E3 or UT (WT) 
T cells and 2 + 1 BiAb. Experiments show mean values ± SEM and are representative of 3 independent experiments. 
Impedance-based cytotoxicity assays were performed in duplicates for technical reasons. For statistical analysis, an 
unpaired student t test was used (A and B). For impedance-based readouts (C and D), the total curve over time was 
compared. 
 
To further dissect the mode of action of SAR T cells in these settings, we next thought to analyze 
the interface between both cell types. Cell conjugates and synapses formed between the T cells 
and tumor cells were subjected to double color immunofluorescence labeling. The number of T 
cell-target cell conjugates were quantified. To probe the nature of the immunological synapse, we 
assessed F-actin and CD11a-LFA-1 accumulation. IS functionality was judged by the polarization 
of the microtubule organizing center (MTOC).  
 
E3 SAR T cell-target cell conjugates occurred much more frequently than UT T cell-target cell 
conjugates, while E3del T cells interestingly formed a comparable number of synapses (Figure 7A). 
Indicative of a functional immune synapse is the strong accumulation of F-actin, which was 
observed to span the entire area of the synapse. MTOC polarization was significantly higher in 
SAR-target cell conjugates compared to UT and E3del controls (Figures 7B). A moderate 
accumulation of LFA-1 signal was seen at the immune synapse, although the LFA-1 signal was 
also observed across the T cell surface (Figure 7C). Human SAR T cells appeared to utilize the 
granzyme-perforin axis for target cell lysis under these settings, as granzyme B accumulation and 




Figure 7: E3 SAR T cells form functional immune synapses. (A and B) E3, E3del and UT T cells were cocultured 
with Suit-MSLN tumor cells in a V-well plate following the described conjugation assay method. The percentage of T 
cells in conjugate with tumor cells was quantified (A), as well as the percentage of those conjugates which has a 
polarized MTOC (E3 formed significantly more conjugates than E3del (p = 0.04)) (B). (C) Double Immunofluorescence 
labelling was carried out to look at the polarization of the MTOC, Granzyme B, LFA-1 and F-actin at the IS. For statistical 
analysis the unpaired two-tailed student’s t test was used. Experiments in subfigures (A and B) show mean values ± 
SEM and are representative of two independent experiments. Subfigure D is representative of two independent 
experiments. Leica TCS SP5 confocal system with a HCX PL APO CS 63x/1.4 oil objective was used for image 
acquisition on Leica application suite v2.7.3.9723. Tumor cells were GFP positive. Fluorochromes used: MTOC (AF594) 
Granzyme B (AF647); F-actin (AF647); LFA-1 (AF647); Lck (AF647). 
 
3.5 Recombinant protein inhibition of SAR-BiAb activity 
We wanted to assess the potential impact of non-tumor or T cell-derived MSLN and EGFRvIII 
proteins on platform functionality. To achieve this, we used recombinant MSLN and EGFRvIII 
proteins. Proteins were added in ascending concentrations to a T cell-tumor cell coculture to look 
at T cell killing efficiency and kinetics. 
 
Saturating concentration of EGFRvIII did not appear to have an impact on killing efficiency nor 
killing kinetics. However, ascending concentrations of recombinant MSLN appeared to have an 
inhibitory effect on T cell killing (B). Nevertheless, the concentrations where this effect was 
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observed were supra-physiological. Thus, it appears that the SAR T cell- BiAb platform is not 










Figure 8: Recombinant protein inhibition of SAR-BiAb axis. (A) Real-time quantification of the impact of 
recombinant EGFR (15 μg/ml) (A) and MSLN (0.5, 10 and 30 μg/ml) (B) on Suit-MSLN-mediated killing by E3 SAR T 
cells and BiAb combination. (A and B) 2 x 105 T cells were cocultured with 2 x 104 Suit-MSLN tumor cells. A 5μg/ml 
concentration of BiAb was used. Experiments shown are representative of 2 independent experiments. These 
impedance-based cytotoxicity assays were performed in duplicates for technical reasons. For statistical analysis, the 
total curve over time was compared. 
 
3.6 Selective and reversible activation of SAR T cells and their applied 
safety-switches  
To demonstrate the selective advantages of the SAR x BiAb platform over BiTE, E3 SAR T cells 
were serially titrated in a PBMC mix, then cocultured with target cells and either a pan T cell-
targeting T cell bispecific antibody (TCB) (anti-CD3 x anti-MSLN) or a SAR-specific BiAb (anti-E3 
x anti-MSLN). The selective activation of SAR T cells was evident when the SAR x PBMC mix 
was coincubated with an anti-EGFRvIII x anti-MSLN BiAb, as IFN-γ levels decreased with lower 
concentrations of SAR T cells in the mix.  
 
This titrated T cell activation effect was lost when the anti-CD3 x anti-MSLN BiAb was employed 
at equivalent total cell numbers. Further, the anti-EGFR x anti-MSLN BiAb did not mediate any T 
cell activation when incubated with a pure PBMC mix devoid of SAR T cells, whereas the anti-
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CD3 x anti-MSLN BiAb was non-selective in activating CD3+ T cells in the PBMC mix, as expected 
(Figure 9A). 
 
An intrinsic safety switch of the SAR x BiAb platform is that the activity of SAR T cells is strictly 
dependent on the presence of the BiAb. Unlike CAR T cells, the activity of which is irreversible in 
the presence of the target antigen, SAR T cell activity should quickly dissipate with clearance of 
the BiAb. This could be demonstrated following coculture with Suit-MSLN tumor cells, as SAR T 
cell activity was reversible over time in the absence of BiAb redosing, unlike human anti-MSLN 
CAR T cells. Importantly, repeated dosing of the BiAb molecule could maintain SAR activity at 
comparable levels to that of the CAR (Figure 9B). This data indicates that the short half-life of the 




Figure 9: Modular, selective and reversible activation of SAR T cells and their applied safety switches. (A) SAR 
T cells were serially titrated (1:10, 1:20, 1:40, 1:60, 1:80, 0:100) in a PBMC mix. Cells were then cocultured with Suit-
2-MSLN tumor cells (E:T - 10:1), with either a pan-T cell-BiAB (anti-CD3–anti-MSLN, 5 μg/ml) or a SAR-specific BiAb 
of the same format (anti-E3–anti-MSLN, 5 μg/ml). (B) E3-MSLN BiAb selectively activates E3 T cells while its depletion 
results in rapid and complete reversibility of SAR T cell stimulation. For BiAb depletion, Suit-2-MSLN tumor cells were 
repeatedly cocultured with E3 T cells with or without readjustment of the BiAb concentration (5 μg/mL). Control condition 
utilized anti-MSLN-CAR T cells (E:T 10:1). For statistical analysis the unpaired two-tailed student’s t test was used. 
Experiments show mean values ± SEM and are representative of at least two independent experiments. 
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3.7 Impact and functionality of SAR-BiAb combination in pancreatic cancer 
xenograft models 
To assess the functionality of the SAR T cells and BiAb combination in vivo, pancreatic cancer 
and mesothelioma xenograft models were developed. The three models developed for testing 
were MiaPaca-MSLN, Suit-MSLN and MSTO-MSLN. E3 T cells plus BiAb mediated anti-tumor 
responses in all three tumor models (Figure 10 A-D). In addition, mice where challenged at two 
tumor sizes (<10 mm2 and <25 mm2), with a therapeutic benefit still being observed when larger 






















Figure 10. Anti-human mesothelin anti-EGFRvIII 2 + 1 BiAb specifically stimulates SAR T cells and mediates 
tumor killing in pancreatic cancer xenograft models. (A) NSG mice inoculated s.c. with MIA PaCa-MSLN were 
treated with a single i.v. injection of E3 T cells only (n = 6), E3 T cells + 10 µg BiAb (n = 10), E3del T cells + 10 µg BiAb 
(n = 6), C3 T cells + 10 µg BiAb (n = 6), 10 µg BiAb only (n = 6), and PBS (n = 6), followed by a total of 10 BiAb 
injections as indicated. (B) NSG mice inoculated s.c. with Suit-2-MSLN were treated with a single i.v. injection of E3 T 
cells only (n = 5), E3 T cells + 20 µg BiAb (n = 10), E3 T cells + 5 g BiAb (n = 5), E3del T cells + 20 µg BiAb (n = 5), C3 
T cells + 20 µg BiAb (n = 5), 20 µg BiAb only (n = 5), and PBS (n = 5), followed by a total of four BiAb injections as 
indicated. NSG mice inoculated s.c. with MSTO-MSLN-LUC were treated with a single i.v. injection of E3 T cells only 
(n = 5), E3 T cells + 10 µg BiAb (n = 5), 10 µg BiAb only (n = 5), and PBS (n = 5), followed by a total of four BiAb 
injections as indicated. NSG mice inoculated s.c. with 1 x 106 MiaPaca MSLN (A), MSTO-MSLN-LUC cells. When 
tumors reached the size of < 25 mm2, mice were treated with a single i.v. injection of E3 T cells only (n=5), E3 T cells 
+ 10 µg BiAb (n=5), 10 µg BiAb only, (n=5), and PBS (n=5), followed by a total of four BiAb injections, as indicated. 
Analysis of differences between groups for the tumor growth curves was performed using two-way ANOVA with 
correction for multiple testing by the Bonferroni method. 
 
In the MSTO-MSLN-LUC xenograft model, we could observe significant infiltration and 
persistence of E3 T cells in the treated mice 23 days following adoptive transfer, which was not 
seen in control groups (Figure 11A, C and D). This tumor T cell infiltrate consisted predominantly 
of CD4+ SAR T cells, though CD8+ SAR T cells were also present (Figure 11A) - In the MSTO-
MSLN-LUC cell-line, a luciferase signal could be used to quantify and show tumor cell persistence 
at experimental end-point (Figure 11 B).  
 
Figure 11. SAR T cell phenotype, infiltration as well as luciferase-based readout from MSTO-MSLN-LUC 
xenograft experiment. (A) FACS-based quantification of E3 T cell compartments before therapy administration, and 
the intra-tumoral infiltrate following tumor harvest at day 25 of MSTO-MSLN-LUC xenograft treatment experiment. Inner 
circle, CD4 and CD8 ratios. Outer circle, ratio of transduced and un-transduced T cells within each compartment. (B) 
Representative NSG mice from MSTO-MSLN-LUC xenograft treatment experiment are depicted. Tumor persistence in 
both treated mouse (right hand side) and control treated mouse (left hand side). Differences in luminescence shown in 
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radiance scales underneath. (C and D) Tumors from the mice in MSTO-MSLN-LUC xenograft experiment (Figure 10 
D) were FACS analyzed for T cell infiltration. Following a drill down through the CD45 and CD3 gates, the EGFR+ CD4 
(C) and CD8 (D) T cell populations were quantified and are depicted as a ratio of cells per bead. In vitro experiments 
show mean values ± SEM of at least triplicates and are representative of at least three independent experiments. P 
values are based on two-sided unpaired t test.  
 
LDH, urea, AST and ALT serum levels remained within the normal range for both E3 T cell plus 
BiAb- and E3del T cell plus BiAb-treated mice, showing no systemic parameters of kidney or liver 










Figure 12: Serum readout of several toxicity markers following SAR-BiAb treatment combination. (A, B, C, D) 
LDH (A), urea (B), AST (C) and ALT (D) serum levels comparing E3 + 2+1 BiAb treated mice with the control mice 
receiving E3del + 2+1 BiAb. Serum was collected at indicated experimental endpoint of MSTO-MSLN-LUC xenograft 
treatment experiment (see Figure 10). Data collected from 5 mice per group. Experiment shows mean values ± SEM. 
P values are based on two-sided unpaired t test.  
 
To investigate whether the observed in vitro reversibility of SAR T cell activity could also be 
observed in vivo, we used the Suit-02-MSLN xenograft model to compare tumor growth in mice 
that were redosed with BiAb with mice that received a single dose. Despite transient tumor control 
(P = 0.026 on day 12), non-redosed mice lost tumor control compared with redosed mice (Figure 
13A). To link these findings to limited T cell activation, mice were bled repeatedly, and serum 
IFN-γ concentration levels were quantified. We found T cell stimulation was reversible in non-
redosed versus redosed mice as a function of time (Figure 14 B). In summary, we could show 
 34 
that SAR T cell activity is limited to the continued presence of the BiAb, which unlike for CAR T 










Figure 13: Reversibility of SAR T cell activation upon BiAb depletion, in vivo. (A and B) NSG mice inoculated s.c. 
with Suit-2-MSLN (n = 5 / group) were treated with a single i.v. injection of E3 T cells only, E3 T cells + 10 μg BiAb—
redosed, E3 T cells + 10 μg BiAb—single dose and PBS followed by a total of six BiAb injections as indicated. 
Significance of non-redosed group versus E3 only at day 12 (P = 0.026; E). Mice were bled 3, 6, 10, and 16 days after 
T cell transfer to quantify T cell activation by IFN-γ serum levels (F). Data are reported normalized to the values obtained 
from the single-dose group. Experiments show mean values +/- SEM and are representative of one independent 
experiment. Analysis of differences between groups for the tumor growth curves was performed using two-way ANOVA 
with correction for multiple testing by the Bonferroni method (A). P value based on two-sided unpaired t test (B). P < 










The experiments presented in this thesis set out to characterize and demonstrate the efficacy of 
the SAR-BiAb platform in the human system. Through this work, we could show that BiAbs can 
mediate specific and conditional activation of human T cells transduced with the E3 SAR 
construct. We could further show that SAR T cells are able to form a distinct and functional IS 
with their target cells to mediate MHC-independent tumor cell lysis. In vivo, substantial antitumoral 
effects could also be shown in two pancreatic cancer and one mesothelioma xenograft model. In 
the solid tumor models, SAR T cell in vivo persistence and tumor infiltration could also be 
observed. SAR T cell activation was shown to be controllable and reversible with BiAb dosage 
and depletion, in vitro and in vivo. Unlike murine SAR T cells, the mechanism of killing employed 
by human SAR T cells was shown not to be reliant on the Fas-FasL axis, although the exact 
mechanism is yet to be shown. 
 
4.1 SAR and BiAb design for controlled T cell activation and tumor cell lysis 
The rationale upon which the platform was built required the careful design of two entities, the 
SAR and the BiAb.  
 
4.1.1 SAR Design 
A crucial aspect of SAR design was the identification of a rare and inert extracellular receptor 
domain that could be selectively triggered to crosslink, ultimately propagating an activation signal 
intracellularly. It was important to the clinical translation of this therapeutic platform that the 
antigen was restricted to the transduced T cells to avoid unwanted binding of the BiAb to non-
tumor tissues. One such receptor is the epidermal growth factor receptor variant III (EGFRvIII). 
Its reported expression in the human system is restricted to certain tumor entities, notably 
associated with increased proliferation of glioma cells (Montano et al. 2011) ). A splice variant of 
the epidermal growth factor receptor (EGFR), it is an in-frame deletion of exons 2 and 7, followed 
by the introduction of a glycine residue where exons 1 and 8 meet, that results in its altered 
transcription. Several reports have cited its inability to bind the natural EGFR ligand EGF, despite 
its binding site (in the L2 region of domain 3) being conserved in the splice variant (Woltjer et al. 
1992)  . It has been postulated that the altered architecture of EGFRvIII is the cause of this (Gong 
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et al. 2014,Huang et al. 1997) . EGFRvIII is known to mediate a constitutive, ligand-independent 
signaling due to the formation of transient homodimers which are stabilized by disulfide bonds of 
free amino-terminal cysteines C16. Although we have not observed ligand-independent signaling 
in our studies, the dimerization can be abolished by mutating the respective cysteine residue 
(Ymer et al. 2011) . C16 is not involved in BiAb engagement and thus could be mutated if any 
spontaneous dimerization of the SAR occurs. It is of relevance that the EGFR-specific monoclonal 
antibodies cetuximab and panitumumab have been shown to possess comparable affinities for 
EGFRvIII (Gong et al. 2014,Patel et al. 2007) ). The utility of this finding lies in the ability to target 
genetically engineered SAR T cells, which could be crucial as a safety switch, through which 
engineered cells expressing the receptor could be depleted (Paszkiewicz et al. 2016) . 
 
Although a rare occurrence, the reported expression of EGFRvIII in the human system means the 
situation where EGFRvIII is no longer an ideal receptor could arise (Montano et al. 2011) . In such 
a case, alternative receptor domains would be required. One such domain is the embryonic gene 
Cripto-1. It is a member of the EGF-Cripto-1/FRL1/Cryptic family and has been implicated in 
embryogenesis as well as carcinogenesis. Importantly, its expression is very low in adult tissues 
and not present on T cells (De Luca et al. 2011) . When membrane-bound, it can potentiate ligand-
dependent signaling, Although binding to its ligand Activin B has been reported, it has been shown 
to have no appreciable binding to TGF-B family ligands (Aykul et al. 2017) . 
 
Designing the intracellular signaling compartment of the SAR, which is made up of the CD3ζ 
stimulatory and CD28 costimulatory domains, was informed by the extensive work carried out 
towards the development of the CAR. Distal to the membrane, the CD3ζ chain was incorporated 
for its role in initializing T cell activation (signal 1). Its use in CAR T cells was first outlined by 
Eshhar and colleagues (Eshhar et al. 1993) and it remains an integral part of CAR design today. 
Proximal to the membrane, and linked to its own transmembrane domain, the intracellular domain 
of the CD28 receptor was added. The signaling domain of the CD28 receptor is important for a 
full physiological T cell activation to be achieved, as it propagates a necessary costimulatory 
signal via PI3K (Krogsgaard et al. 2005,Zhang et al. 2017,Love et al. 2010) . Its combination with 
the CD3ζ domain to form a single chimeric receptor was shown by Maher and colleagues to 
ameliorate T cell cytotoxicity and proliferation (Maher et al. 2002) . The exchange or addition of 
other signaling endodomains, such as 41BB and ICOS, have been shown to have a marked 
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impact on T cell activity, metabolic programing and in vivo persistence (Guedan et al. 2014,Zhong 
et al. 2010).  
 
A SAR containing 41BB as the costimulatory endodomain is an alternative design that warrants 
testing and characterization. Extensive research has been carried out comparing clinically tested 
CAR T cells containing a 41BB costimulatory domain with those containing CD28 (Kawalekar et 
al. 2016) . CD4+ and CD8+ CAR T cells with a 41BB domain were shown to have a prolonged 
proliferation phase and better persistence (through non canonical NF-kB signaling) over those 
containing CD28 (Philipson et al. 2020) . A differentiation status more skewed towards a central 
memory phenotype was observed with 41BB CAR T cells in comparison to CD28 CAR T cells 
(Ying et al. 2019) . T cell activation is linked to a bioenergetics and biosynthetic flux that is needed 
to aid T cell function and persistence (Pearce et al. 2013,Wang et al. 2012) . Naïve and memory 
T cells primarily depend on mitochondrial oxidation, while effector T cells have been shown to 
switch to glycolysis or augmented oxidative phosphorylation and aerobic glycolysis (Pearce et al. 
2009,van der Windt et al. 2013) . Consistent with this and the differentiation status observed when 
comparing 41BB and CD28 CAR T cells, are studies highlighting the metabolic differences 
between 41BB and CD28 CAR T cells (Kawalekar et al. 2016,Menk et al. 2018) . They showed 
that 41BB leads to increased mitochondrial biogenesis and oxidative metabolism, while CD28 
results in decreased mitochondrial biogenesis and increased glycolytic metabolism. Whether 
these findings in CAR T cells could be translated to the SAR-BiAb setting is yet to be shown, 
although evidence suggests it could improve in vivo T cell persistence and antitumoral functions. 
 
Nevertheless, optimal CAR and SAR designs will inevitably depend on the stimulatory or 
phenotypic advantage that is deemed most necessary to equip the T cell with, depending on the 
case and setting. Thus, the extensive testing of different costimulatory domains in various settings 
would still be required, as demonstrated by several preclinical studies in the CAR setting (Guedan 
et al. 2014,Hu et al. 2019,Guedan et al. 2018).  
 
4.1.2 BiAb design 
When designing a BiAb for SAR activation, certain prerequisites must be considered. The binding 
affinity of the tumor-targeting Fab must be designed with consideration for the relative expression 
of its target. A balance that would maximize tumor cell binding while minimizing, if not abolishing, 
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on-target off-tumor binding would be desired. Too low an affinity would compromise tumor 
targeting, while an affinity that is too high would result in off-tumor toxicity (Liu et al. 2015) . If 
safety considerations allow and depending on the tumor entity that is targeted, future BiAb 
designs could have a higher affinity for the tumor antigen (Yuraszeck et al. 2017) . A higher affinity 
would allow a BiAb matrix to be formed on the surface of the tumor cells, upon which SAR T cells, 
with their lower affinity binding to the BiAb, can mediate serial tumor cell killing more efficiently 
(Hoffmann et al. 2005,Herrmann et al. 2018) . This design would also minimize antibody trapping 
in T cell-rich tissues, such as the spleen or lymph nodes, reducing the potential for off-target 
toxicity (Leong et al. 2017,Bortoletto et al. 2002).  
 
The number of valencies directed towards the SAR are critical for the facet of targeted specificity. 
It is imperative that a BiAb must not trigger T cell activation in the absence of the tumor cell. In 
the presence of the tumor cell, the BiAb can aggregate, thereby enabling the SAR receptor to 
crosslink and mediate T cell activation. Early studies using CD3-targeting BiTEs showed that it 
was not possible for the BiTEs to stimulate the T cell lytic capacity simply through binding with 
their anti-CD3 binder to the receptor complex even when tested at concentrations far exceeding 
the EC50 values for redirected lysis (Kufer et al. 1997) . This distinct feature was attributed to the 
monomeric nature of BiTEs, because binding of a BiTE with a single monovalent specificity to the 
CD3 complex was insufficient in mediating a complete T-cell activation. On the other hand, when 
BiTEs were organized on the target cell surface, thus accessible to the T cells in a polyvalent 
form, they resulted in strong T-cell signaling and redirected killing, and a cascade of consequent 
events (Perez et al. 1985,Wolf et al. 2005) . Although the targeted receptor is not the same in the 
case of the SAR (EGFRvIII), the same concept applies. As a result, the cross-linking ability of the 
2 + 1 BiAb is restored in the presence of an immobilizing tumor- associated binding moiety for the 
other arm of the BiAb. 
 
Depending on the disease entity and the level of controllability that is required, BiAb design can 
have a significant impact on both function and half-life. Through binding the FcγR, a functional Fc 
region can mediate antibody-dependent cellular cytotoxicity (Petricevic et al. 2013) . Introduction 
of the P329G LALA mutation in IgG1 antibodies was previously shown to abolish binding to the 
FcγR receptor, rendering the Fc region non-functional (Schlothauer et al. 2016,Klein et al. 2019) 
. In the context of the SAR-BiAb platform, this Fc function is redundant and therefore the BiAb 
was designed to include this mutation in the Fc region.  
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Despite its lack of function, the Fc region of the CrossMab still has an impact on the half-life of 
the molecule. Fc-deficient formats have been shown to have a relatively short plasma half-life as 
they are not protected from catabolism by the neonatal Fc-receptor (FcRn). Should it become 
necessary to modulate this in the future, FcRn binding and recycling can be abolished via the 
introduction of Triple A (I253A, H310A, H435A) mutations into the Fc region, as previously 
described (Regula et al. 2016).  
 
4.2 The importance of the immunological synapse to SAR functionality 
In response to cell-surface stimulation, lymphocytes have the capacity to totally change their 
cellular architecture. It is a structural plasticity that helps to promote and specify interactions 
between T cells and tumor cells. The immunological synapse (IS) is a well-defined cell-cell contact 
formed after the association of adhesion and signaling proteins, as well as cell surface receptors 
into concentric rings (Dustin et al. 2010) . Cytotoxic T cells rapidly and specifically lyse their target 
cell, following the formation of an IS once the TCR has been engaged (Monks et al. 1998) . Upon 
engagement of the (TCR), several concentric rings, known as the supramolecular activating 
clusters (SMAC) make up the IS. Clustered molecules conferring specific functions make up each 
cluster. The central SMAC (cSMAC) is made up of clusters of Lck and TCR, that strengthen the 
cytotoxic response via the buildup of activation signals and the transfer of cytotoxic particles. 
Surrounding the cSMAC is the peripheral SMAC (pSMAC), an accumulation of adhesion 
molecules (made up of LFA-1)) stabilizes the synapse itself as well as target cell binding. An 
aggregation of actin known as the distal SMAC (dSMAC) (Dustin et al. 2014)  The microtubule 
organizing center (MTOC), otherwise known as the centrosome, is an important structure that is 
rapidly reorganized (within 5 minutes of T cell stimulation) to carry with it key vascular components 
such as the golgi apparatus. The reorientation of the MTOC to a point below the cell-cell boundary 
is indicative of functional IS formation. This remodeling of the cytoskeleton in an event which 
aligns secretory organelles within the T cell with the IS (Martín-Cófreces et al. 2008).  
 
It is known that the signaling machinery of CARs shares many aspects with that of the 
conventional TCR (Maher et al. 2002) . It was thus surprising when a study demonstrated 
considerable differences between the IS structure formed by a CAR to that formed by a TCR. 
They could show that LFA-1 is expendable for the IS formation at CAR as well as TCR interfaces. 
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Further, Lck did not cluster within the cSMAC of the CAR IS, with its micropatches forming a more 
disordered pattern. As a result, the inner diameter of the CAR synapse was a lot smaller by 
comparison and is congruent with the earlier CAR T cell detachment that was observed. CAR T 
cells were also shown to deliver lytic granules more rapidly to the synapse, resulting in speedier 
target cell lysis (Davenport et al. 2018) . On the other hand, CD3-targeting BiAbs were shown to 
form functional immune synapses that were comparable to those formed following a classical 
TCR-target cell interaction (Offner et al. 2006).  
 
Given the differences observed at the T cell-tumor cell interface of several ACT approaches, it 
was important to establish both the nature and functionality of the IS formed at the interface 
between SAR T cells and their target cells, and how it compares to the CAR and TCR approaches 
described above. A polarized MTOC and a large F-actin area demonstrated that the SAR-BiAb 
combination could induce the formation of a functional synapse. MTOC translocation towards the 
nascent IS has previously been shown to be an important early step in lymphocyte activation 
initiated by the TCR (Martín-Cófreces et al. 2008) , as well as the CAR (Davenport et al. 2018) . 
Interestingly, MTOC polarization in the CAR T cell IS was more distal from the membrane when 
compared to TCR T cells, the localization in which was more proximal to the membrane, and 
close to Lck. In this regard, the MTOC polarization observed in SAR T cells was more comparable 
to that observed in TCR T cells, given its close proximity to the membrane. It remains to be shown 
whether MTOC polarization in SAR T cells also localizes in proximity to Lck. Granzyme B (GZMB) 
granules were seen to be polarized at the SAR IS in comparable fashion to both TCR and CAR 
T cells (Xiong et al. 2018,Jenkins et al. 2010) . The LFA-1 organization pattern at the SAR T cell 
IS was disorganized and comparable to that observed at the IS formed by CARs (Davenport et 
al. 2018). This is contrary to the LFA-1 organization pattern at the IS of TCR T cells, which is 
comprised of an organized bull’s eye structure (Davenport et al. 2018). A more comprehensive 
side-by-side comparison of the IS formed by SAR, CAR and TCR T cells will need to be carried 
out to further validate and better understand the differences observed. 
 
4.3 Target antigen specificity and the conditional activation of human SAR T 
cells for tumor cell lysis 
Specific and conditional SAR stimulation and targeted tumor cell lysis was observed when the 
SAR, BiAb and targeted antigen were present. Furthermore, the targeted specificity of the 
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platform was tested to investigate whether the expression of EGFRvIII could stimulate our T cells, 
and whether SAR T cells would subsequently mediate cytotoxicity of EGFRvIII-positive cells. 
Cytotoxicity assays as well as IFNγ and IL-2 cytokine release assays revealed that E3 SAR T 
cells were not able to lyse EGFRvIII-positive tumor cells when compared to MSLN-positive ones, 
which were effectively lysed. We also questioned whether free MSLN or EGFRvIII proteins could 
inhibit or interfere with SAR-BiAb activity and found that ascending concentrations of recombinant 
MSLN could inhibit tumor cell killing. Free targeted protein in the TME must be considered as a 
potential hindrance to the efficacy of the SAR-BiAb combination. This could become especially 
problematic in targeting cleavable proteins, such as MSLN, and the targeting of membrane-
associated forms of proteins could maximize efficiency in this regard (Asgarov et al. 2017) . In 
any case, testing under physiological conditions must be carried out to further validate this finding. 
 
4.4 The selective and modular nature of the SAR-BiAb platform in cancer 
therapy 
While insufficient tumor infiltration and a dense immunosuppressive microenvironment are 
notable hindrances to the success of T cell therapies in solid tumor settings, antigen heterogeneity 
and on-target off-tumor toxicity remain problematic in this regard (Runa et al. 2017).  
 
To overcome these challenges, highly modular and controllable approaches are needed to offer 
flexibility when targeting a diverse set of tumor-associated antigens, and control over the risk of 
toxicities due to attraction to healthy tissue that expresses the antigen (Lesch et al. 2019) . These 
risks cannot be adequately predicted from preclinical data (Fitzgerald et al. 2017,Watanabe et al. 
2018) . The ‘safety switches’ that have been incorporated into the SAR-BiAb platform have been 
shown to have the potential to limit possibly lethal side effects. 
 
A major advantage of the platform we describe is its reversibility with the elimination of the BiAb. 
Elimination of the BiAb, in the event of toxicity or on-target-off-tumor activity, would reverse SAR 
T cell activity. Moreover, the BiAb concentration could then be adjusted accordingly, to maintain 
T cell efficacy and manage possible toxicity. Furthermore, as previously mentioned, SAR T cell 
depletion with anti-EGFR antibodies can act as an additional safety switch. 
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Inter-patient heterogeneity and the diverse antigen profile of many cancer types highlights the 
importance of a modular platform with the potential for redirection towards different targets. In 
terms of modularity, once the T cell arm of the therapy is adoptively transferred, the redirection 
and subsequent activation of SAR T cells is completely dependent on the BiAb. Further or 
sequential targeting of the tumor through the redirection of pre-existing SAR T cells could then be 
achieved through the introduction of a new BiAb with a different antigen specificity. 
 
In the event of target downregulation as an escape mechanism following treatment (most 
prevalent resistance mechanism observed following CD19 targeted treatment in ALL patients) 
(Ruella et al. 2016,Majzner et al. 2018) , platform modularity would again be advantageous. In a 
clinical setting, this treatment approach would allow for the careful monitoring of patients for the 
potential emergence of side effects.  
 
4.5 Approaches to improve SAR T cell functionality 
The SAR-BiAb platform distinguishes between two T cell populations in the patient (engineered 
and non-engineered). This was shown when directly comparing a pan-T cell targeting molecule 
with a SAR-specific one, substantiating the claim that non-engineered T cells are not affected by 
the platform, and differentiating the approach from those using pan-T cell–activating BiAbs. SAR 
T cells can therefore be carefully selected and tailored. In this line, identifying the optimal T cell 
differentiation state that would result in maximal efficacy is an important axis through which the 
SAR-BiAb can be improved. 
 
The impact of defined CD4+ and CD8+ T cell subsets is one important consideration. Several 
reports have shown that defined compositions can have a significant impact on anti-tumoral 
efficacy. One such study in the glioblastoma disease setting showed that CD4+ CAR T cells (anti-
IL13Ra2) mediated superior tumor control in vivo when compared to a mix of CD4+ and CD8+ 
CAR T cells (Wang et al. 2018)  A clinical study by Turtle and colleagues in the B cell ALL setting 
employed CD19 CAR T cells of a defined CD4+ and CD8+ composition, with 93 % of patients 
achieving remission (Turtle et al. 2016) . Discerning if various differing CD4+ and CD8+ ratios can 
have an impact on SAR T cell functionality would be an important finding in this regard.  
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In addition to the introduction of the synthetic construct, additional genetic modifications, including 
targeted transgene integration is another potential approach to improve SAR T cell function, and 
has already been shown to improve anti-tumoral efficacy in CAR T cells. Directing transgenes 
towards specific genomic locations has the potential advantages of optimizing transgene function 
while mitigating unforeseen genotoxicity. One study could reduce tonic signaling (resulting in 
more optimal CAR surface expression levels) in CAR T cells by directing the CAR to the T cell 
receptor alpha constant (TRAC) locus (Eyquem et al. 2017) . In a case study, random lentiviral 
vector integration had serendipitously disrupted the methylcytosin dioxygenase TET2 gene on 
one allele. As the patient harbored a hypomorphic mutation in their second allele, it led to the loss 
of function of TET2 in the patient’s CAR T cell. Astonishingly, 94 % of the patient’s CD8+ T cell 
compartment was TET2 deficient at the peak of response (Fraietta et al. 2018) . The phenotypic 
and functional changes observed in the patient’s CAR T cell subset that were correlated with 
improved persistence and response were recapitulated in further in vitro studies, showing TET2 
to be a potential axis for improved CAR T cell function.  
 
Several gene-editing approaches including CRISPR/Cas9, zinc finger nucleases and TALENs 
have been successfully used to disrupt T cell suppressive genes in T cells. A recent clinical study 
was conducted in patients with refractory cancer and showed the potential of CRISPR-cas9 edited 
T cells for cancer therapy (Stadtmauer et al. 2020,Hamilton et al. 2020,Lu et al. 2020) . The 
application of these approaches for the improvement of SAR T cell functionality has a lot of 
promise.  
 
4.6 in vivo functionality – Understanding the shortcomings and room for 
improvement 
As previously mentioned, the use of both CD4+ and CD8+ T cell subpopulations has been shown 
to be required for efficient and durable clinical responses to ACT (Turtle et al. 2016) . The SAR 
used in this study could be successfully transduced in CD4+ and CD8+ human T cells with great 
efficiency. Higher tumor infiltration and longer persistence in vivo by CD8+, and especially CD4+ 
SAR T cells emphasize the necessity of both cell types for the observed anti-tumoral responses. 
Impaired migration and activation of T cells within tumor tissue are major limiting factors linked to 
the poor success of advanced T cell–based therapies in solid tumor settings (Slaney et al. 
2014,Kmiecik et al. 2013,Galon et al. 2006,Piersma et al. 2007) . SAR T cells achieved long-
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lasting tumor control in vivo but failed to completely eradicate established tumors, and these 
limiting factors are likely to play a role. 
 
As described above, exchange of the signaling endodomains or the addition of structural 
components was observed to boost the in vivo performance of various CARs. As such, the impact 
of further modifications to SAR design must be investigated in search of strategies to ameliorate 
the in vivo functionality (Lim et al. 2017) . The additional engineering of SAR T cells with selected 
chemokine receptors might overcome their limited infiltration into tumor tissue (Rapp et al. 2016) 
. Further, the use of dominant- negative TGF-β receptors (Foster et al. 2008) or PD-1-CD28 
(Kobold et al. 2014) switch receptors could help shield the modified T cells from the 
immunosuppressive tumor microenvironment. It is thus reasonable to postulate that treatment 
failure occurs due to insufficient persistence, recruitment and infiltration of the transferred T cells 
into the tumor and is a matter of ongoing investigations to improve SAR T cell efficacy. 
 
The in vivo downregulation of the MSLN antigen on the tumor cell surface is another potential 
contributing factor. We applied ex-vivo flow cytometry analysis of tumor tissue in an attempt to do 
this. However, MSLN expression could not be accurately quantified, as a result of suboptimal 









5 Conclusions and outlook 
 
In conclusion, we describe a novel modular platform for MHC- unrestricted SAR T cell–based 
therapy with properties distinct from current approaches. Taken together, the SAR–BiAb platform 
aligns the advantages of antibody therapy (controllable dosing and reversibility) with that of 
adoptive T cell therapy (potent anti-tumoral effectors) (Karches et al. 2019,Slaney et al. 2018) . 
 
Beyond what has been demonstrated in the solid tumor setting, the application of this platform for 
the treatment of hematological diseases is very appealing. The most prevalent resistance 
mechanism observed following CD19-targeted therapy is target downregulation (Ruella et al. 
2016) . The modularity of the SAR-BiAb platform would offer a flexibility to change the target and 
redirect the already transferred effector cells if such an event were to occur. In addition, its 
application in the AML disease setting could also be of interest. Perhaps the greatest challenge 
hindering the success of adoptive T cell therapy in AML is target specificity, which results from 
disease heterogeneity and diverse antigen expression on leukemic stem cells (Haubner et al. 
2019,Perna et al. 2017) . A patient-specific multi-targeting approach, where BiAbs are added in a 
simultaneous or sequential manner is an approach that warrants further investigation. 
 
While further development of the separate components, and more extensive testing within and 
across tumor models is still required before its application in a clinical setting, the SAR-BiAb 
platform undoubtedly offers new solutions in tumor settings in need of more modular and 
controllable approaches.
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6 Abstract                
 
Adoptive T cell therapy, namely chimeric antigen receptor (CAR) T cell therapy has been a 
groundbreaking and effective treatment of relapsed or refractory haematological malignancies. 
Still, many patients do not respond or relapse with treatment-resistant disease. Additionally, 
toxicities such as cytokine release syndrome remain problematic. Cancer heterogeneity, beyond 
cancer types and inter-patient differences, is present within every individual patient. This 
heterogeneity, especially in the context of solid tumors, has meant that targeted immunotherapies 
have fared relatively poorly, creating a need for a modular platform with a capacity to target 
multiple antigens simultaneously and/or sequentially. Likewise, treatment-related toxicities have 
limited the therapeutic efficacy and breadth of patient selection.  
 
To tackle these caveats through a modular and controllable approach, we equipped T cells with 
synthetic agonistic receptors (SARs) that are only activated when a tumor-associated antigen and 
a cross-linking bispecific antibody (BiAb) specific for both SAR T cell and tumor cell are also 
present. The SAR itself is constituted of an inert extracellular domain in the form of EGFRvIII, that 
is fused to the T cell activating domains CD28 and CD3ζ. The BiAb employed is a trivalent 
CrossMab, with two binding arms (2 x Fab) for the tumor-associated antigen (mesothelin), and 
one binding arm for the SAR receptor (EGFRvIII). 
 
We showed that BiAb triggering of the SAR is conditional upon the binding of the second BiAb 
specificity. What is particularly advantageous with this approach is that T cell activation may only 
occur when the BiAb is present and in proximity to the antibody-targeted tumor cell. This 
conditional T cell activation is an inherent safety feature of the platform, whereby if unwanted 
levels of T cell activation are observed, depletion of the BiAb from the system could result in the 
reversal of said activation, thus managing the potential toxicity. 
 
This work was able to determine the validity and efficacy of the approach. Through the generation 
of several human pancreatic cancer models, and extensive in vitro and in vivo testing, the platform 
could be characterized. Its translational relevance and significance as a next-generation adoptive 
T cell therapy with the potential to plug some gaping pitfalls of current ACT approaches were also 
shown. 
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ACT Adoptive T cell therapy 
ALL Acute lymphoblastic leukemia 
AML Acute myeloid leukemia 
APC Antigen presenting cell 
BiAb Bispecific antibody 
BiTE Bispecific T cell engager 
CAR Chimeric antigen receptor 
CD Cluster of differentiation 
CRISPR Clustered regularly interspaced short 
palindromic repeats 
CrossMab Immunoglobulin domain crossover 
DNA Deoxyribonucleic acid 
EGFR Epidermal growth factor receptor 
EGFRvIII Epidermal growth factor receptor variant three 
EGTA  Egtazic acid 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
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FcRn Neonatal Fc receptor 
FcγR Fc gamma receptor 
FasL Fas ligand 
FDA Food and Drug Administration 
ffLuc Firefly luciferase 
GZMB Granzyme B 
ICOS Inducible T cell costimulator 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin  
IS Immunological synapse 
ITAM Immunotyrosine activation motif 
KiH Knob into hole 
Lck Lymphocyte-specific protein tyrosine kinase 
LFA-1 Lymphocyte function-associated antigen 1  
MCS Multiple cloning site 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
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MTOC Microtubule organizing centre 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PI3K Phosphoinositide 3-kinase 
SAR Synthetic agonistic receptor 
scFv Single chain variable fragment 
SEM Standard error of the mean 
SMAC Supramolecular activation cluster 
TALEN Transcription activator-like effector nuclease 
TCR T cell receptor 
TET2 Tet methylcytosine dioxygenase 2 
TME Tumor microenvironment 
TIL Tumor infiltrating lymphocyte 
TRAC T cell receptor α constant 
TGF-b Tumor growth factor-b 








TNFR Tumor necrosis factor receptor 
UT Untransduced 




1. Mohamed-Reda Benmebarek*, Clara Helke Karches*, Bruno Loureiro Cadilha, Stefanie 
Lesch, Stefan Endres and Sebastian Kobold (* contributed equally).  
Killing mechanisms of chimeric antigen receptor (CAR) T cells.  
International Journal of Molecular Science 2019; 20:1283  
 
2. Clara Helke Karches*, Mohamed-Reda Benmebarek*, Moritz Luigi Schmidbauer, Mathias 
Kurzay, Richard Klaus, Martina Geiger, Felicitas Rataj, Bruno Loureiro Cadilha, Stefanie Lesch, 
Constanze Heise, Ramona Murr, Johannes vom Berg, Martin Jastroch, Daniel Lamp, Jian Ding, 
Peter Duewell, Gerhard Niederfellner, Claudio Sustmann, Stefan Endres, Christian Klein and 
Sebastian Kobold (* contributed equally).  
Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor 
immunotherapy.  
Clinical Cancer Research 2019; 25:5890-900. 
 
3. Stefan Stoiber, Bruno Loureiro Cadilha, Mohamed-Reda Benmebarek, Stefanie Lesch, Stefan 
Endres, Sebastian Kobold.  
Limitations in the design of chimeric antigen receptors for cancer therapy.  
Cells 2019; 8:472 
 
4. Stefanie Lesch*, Mohamed-Reda Benmebarek*, Bruno Loureiro Cadilha*, Stefan Stoiber*, 
Marion Subklewe, Stefan Endres, Sebastian Kobold (* contributed equally).  
Determinants of response and resistance to car t cell therapy.  
Seminars in Cancer Biology 2019.  
  
 67 
11 Acknowledgements   
 
I would like to thank my host institution, the Ludwig-Maximilians-Universität München for the opportunity 
to complete my doctoral title at such a brilliant university. 
More than anywhere else, The Division of Clinical Pharmacology has been my home for the better part 
of the last four years. I am grateful to have had the pleasure to develop and learn in such a nurturing and 
friendly environment. I will forever be connected and in debt. 
I had the opportunity to be a part of the best PhD program anyone could ask for. The European Training 
Network Immutrain was an experience to cherish. Through my experiences and training opportunities, I 
learned so much about the importance of collaboration, international mobility and the need to always 
strive to be better. A big thank you to Marie Sklodowska-Curie Actions and the European Commission, 
and of course to Seb and Stefan for making it happen, it was a blast. 
My fellow Immutrainees, such a wonderful bunch of grounded, driven and kind young scientists. I 
thoroughly enjoyed our European tour together. I’m sure our paths will continue to cross. The Munich 
crew, Alex, Javi, Leo and Adele you guys were there during the best and most challenging times. I 
couldn’t have done it without you. Abbass, it was a true pleasure, beyond the fruitful collaborations and 
work, our project development sessions are especially memorable. 
Bruno, working together with you has been a pleasure and an honour, I learned so much from you. I’m 
sure this is just the beginning bruv. 
Stoiber, more than the hive mind sessions and fresh air, it was a pleasure to get to know you. 
A big thank you to Martina and Ramona for their swift help, antibody production and collaboration. 
Thank you to Christian Klein for mentoring me throughout my doctoral studies. You’ve been a great 
example and mentor and have played an important part in my continued scientific development. I am 
enjoying our continued scientific collaboration. 
Seb, or Professor Kobold now J, I am forever grateful for the opportunity you gave me in allowing me to 
join your group. You played the most important role in my scientific development. Beyond that, you taught 
about the necessity to love what I do. Your outstanding critical thinking, planning and discipline continue 
to impress me on a regular basis, as I continue to learn from you. You’re a wonderful boss. Thank you, 
 68 
Stefan Endres, I couldn’t think of a better Division leader even if I had to make one up. The way in which 
you run your division is utterly brilliant. It is thanks to you that we have such a wonderful place to work 
and develop. Your guidance and continued reinforcement have been and continue to be invaluable to 
me. Thank you. 
Alex and GM, my brothers. Being with you has shaped who I am today. You know how important you 
are. HJ our soldier, I’m sure we’ll meet again soon. George and Rubz, your potential is endless, and I am 
proud of you both. 
To all my friends that I didn’t mention, you know who you are and how important you’ve been to me and 
my journey. 
King’s College London, my stomping ground for more than half a decade. I am so grateful for my time 
there. I learned the importance of being better and never settling for mediocre. I am grateful for all the 
friends I made there, thank you! Shahram and Alan, I couldn’t have asked for a better pair of supervisors 
who allowed me to develop as well as make mistakes. 
To all my teachers and friends at Christ’s College Finchley, you were so important to my development as 
a student and as a person. Special mention to my Biology teacher Mrs Terry and my Chemistry teacher 
Mr. Persaud. Thank you! 
Marina, amor meu. No ho hauria pogut fer sense tu! I joke and call you my ball and chain, but in reality, 
you are my rock, without whom I’d be lost. We got through this journey together. I know it is just the 
beginning and I can’t wait for what’s to come. 
To my family. Sakina and Samir, without all the sacrifices you made for us none of us would be where 
we are today. You are wonderful parents and everything I have I owe to you! Serine, Houda, Esme, Adam 
and Idris. Your love and support mean so much to me!  
This thesis is dedicated to my grandfather Abdesslem Ouarezguia. 
 
 
 
 
 
